blinatumomab Injection

Brand(s)
Blincyto
Category(s)
prescription
SPL Type(s)
Human Prescription
Master SPL
Amgen Inc (2014-12-16)
Oldest Current Product
2014-12-18
License(s)
BLA
RxNORM
INJECTION\BLINATUMOMAB

product(s) by strength(s)

blinatumomab 0.035 mg injection

original product(s)(s)

#idbrandcategorylabelerfirst marketedapplicationspl
1555130160BlincytoBLAAmgen Inc2014-12-1812555738b482a8-960b-4591-9857-5031ecb830aa

application(s)

#idtitleapprovedtradenamesfda division
1125557blinatumomab Application2014-12-03BlincytoCDER

spl(s)

#idtitlecategorytypelabelerlast updateversionproduct(s)
138b482a8-960b-4591-9857-5031ecb830aa (view SPL)These highlights do not include all the information needed to use BLINCYTOTM safely and effectively. See full prescribing information for BLINCYTO. BLINCYTO (blinatumomab) for injection, for intravenous use Initial U.S. Approval: 2014prescriptionHuman PrescriptionAmgen Inc2014-12-167555130160

Data from: FDAOB, FDAPB, LOINC, MTHSPL, NDFRT, NCIT, RxNORM, UNII